Outset Medical (NASDAQ:OM) Price Target Lowered to $8.00 at Stifel Nicolaus

Outset Medical (NASDAQ:OM) had its price objective decreased by stock analysts at Stifel Nicolaus from $14.00 to $8.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target indicates a potential upside of 91.66% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $7.00 price objective on shares of Outset Medical in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Finally, BTIG Research restated a “buy” rating and set a $17.00 price objective on shares of Outset Medical in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.67.

Outset Medical Price Performance

Shares of NASDAQ OM opened at $4.17 on Wednesday. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. The company has a market cap of $75.76 million, a PE ratio of -0.33 and a beta of 2.07. Outset Medical has a twelve month low of $3.10 and a twelve month high of $21.98. The business’s 50 day moving average price is $5.72 and its two-hundred day moving average price is $12.11.

Institutional Investors Weigh In On Outset Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new position in shares of Outset Medical in the 2nd quarter valued at $34,000. Ameritas Investment Partners Inc. bought a new position in Outset Medical in the second quarter valued at about $35,000. BNP Paribas Financial Markets raised its stake in Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after acquiring an additional 2,034 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Outset Medical in the second quarter worth about $78,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Outset Medical in the 2nd quarter valued at approximately $108,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.